Stuck in the middle

Article Abstract:

MediciNova, the first foreign-based biotechnology company to list its shares in Japan, is caught up in bureaucratic problems, with rules on trading of shares of foreign firms resulting in a steep fall in the share value. A step-by-step approach is recommended in Japanese systems, and other foreign biotech companies that might list on a Japanese stock market are waiting to be better prepared before they choose Japan as a base for raising money.

Japan, Securities issued, listed, Securities, Company securities

---

Anaemic outlook for Amgen

Article Abstract:

The article describes the problems faced by Amgen, a biotechnology company in California, U.S. The problem relates to the anti-anemia drugs produced and manufactured by Amgen.

Sales, profits & dividends, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Hematinic Preparations, United States, Usage, Company sales and earnings, Company earnings/profit, Hematinics, Amgen Biologicals/Diagnostics

---

Similar abstracts:

• Abstracts: Stem-cell brothers divide. Where now for stem-cell cloners? . Victims hit out at university over handling of harassment cases
• Abstracts: Swooping for biotech. Meeting in the middle. No longer the upstart
• Abstracts: Getting the right mix. Scientists attack Bush over intelligent design. Special report
• Abstracts: Among the best. Indian voices. Scientists unite in bid to drive policy
• Abstracts: Pumping up the volume. Designs on Europa unfurl. A measure of happiness

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.